BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3366493)

  • 1. Uptake of glutamine antimetabolites 6-diazo-5-oxo-L-norleucine (DON) and acivicin in sensitive and resistant tumor cell lines.
    Huber KR; Rosenfeld H; Roberts J
    Int J Cancer; 1988 May; 41(5):752-5. PubMed ID: 3366493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of antitumor activity of glutamine antagonists 6-diazo-5-oxo-L-norleucine and acivicin in cell culture by glutaminase-asparaginase.
    Rosenfeld H; Roberts J
    Cancer Res; 1981 Apr; 41(4):1324-8. PubMed ID: 7214322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.
    Huber KR; Mayer EP; Mitchell DF; Roberts J
    Br J Cancer; 1987 Jun; 55(6):653-6. PubMed ID: 3620309
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Jayaram HN; Ardalan B; Deas M; Johnson RK
    Cancer Res; 1985 Jan; 45(1):207-12. PubMed ID: 2578092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of L-glutamine antagonists on 5-phosphoribosyl 1-pyrophosphate levels in P388 leukemia and in murine colon adenocarcinomas in vivo.
    Ardalan B; Arakawa M; Villacorte D; Jayaram H; Cooney DA
    Biochem Pharmacol; 1982 Apr; 31(8):1509-13. PubMed ID: 6178415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport and membrane binding of the glutamine analogue 6-diazo-5-oxo-L-norleucine (DON) in Xenopus laevis oocytes.
    Taylor PM; Mackenzie B; Hundal HS; Robertson E; Rennie MJ
    J Membr Biol; 1992 Jun; 128(3):181-91. PubMed ID: 1501246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic mechanisms of glutamine antagonists in mouse L1210 leukemia.
    Lyons SD; Sant ME; Christopherson RI
    J Biol Chem; 1990 Jul; 265(19):11377-81. PubMed ID: 2358467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 6-DIAZO-5-OXO-L-NORLEUCINE INHIBITION OF ESCHERICHIA COLI.
    COGGIN JH; MARTIN WR
    J Bacteriol; 1965 May; 89(5):1348-53. PubMed ID: 14293024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
    Ardalan B; Jayaram HN; Johnson RK
    Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of glutamine and glucose analogues in metabolic inhibition of human myeloid leukaemia in vitro.
    Griffiths M; Keast D; Patrick G; Crawford M; Palmer TN
    Int J Biochem; 1993 Dec; 25(12):1749-55. PubMed ID: 8138012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acivicin: a new glutamine antagonist in clinical trials.
    O'Dwyer PJ; Alonso MT; Leyland-Jones B
    J Clin Oncol; 1984 Sep; 2(9):1064-71. PubMed ID: 6470756
    [No Abstract]   [Full Text] [Related]  

  • 12. Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.
    Wang SZ; Poore B; Alt J; Price A; Allen SJ; Hanaford AR; Kaur H; Orr BA; Slusher BS; Eberhart CG; Raabe EH; Rubens JA
    Clin Cancer Res; 2019 Oct; 25(19):5925-5936. PubMed ID: 31300448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of glutamine in erythrocytes infected with the human malaria parasite: Plasmodium falciparum.
    Vilmont M; Azoulay M; Frappier F
    Ann Parasitol Hum Comp; 1990; 65(4):162-6. PubMed ID: 1982204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast.
    Willis RC; Seegmiller JE
    J Cell Physiol; 1977 Dec; 93(3):375-82. PubMed ID: 22551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice.
    Ovejera AA; Houchens DP; Catane R; Sheridan MA; Muggia FM
    Cancer Res; 1979 Aug; 39(8):3220-4. PubMed ID: 572261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonizing Bcl-2 family members sensitizes neuroblastoma and Ewing's sarcoma to an inhibitor of glutamine metabolism.
    Olsen RR; Mary-Sinclair MN; Yin Z; Freeman KW
    PLoS One; 2015; 10(1):e0116998. PubMed ID: 25615615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. We're Not "DON" Yet: Optimal Dosing and Prodrug Delivery of
    Lemberg KM; Vornov JJ; Rais R; Slusher BS
    Mol Cancer Ther; 2018 Sep; 17(9):1824-1832. PubMed ID: 30181331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rediscovery of DON (6-diazo-5-oxo-L-norleucine).
    Kisner DL; Catane R; Muggia FM
    Recent Results Cancer Res; 1980; 74():258-63. PubMed ID: 7192426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. gamma-Glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition by glutamine antagonists.
    Waltham MC; Li WW; Gritsman H; Tong WP; Bertino JR
    Mol Pharmacol; 1997 May; 51(5):825-32. PubMed ID: 9145921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transport mechanisms of 6-diazo-5-oxo-L-norleucine in Escherichia coli K-12.
    Williams MV
    Microbiologica; 1982 Jan; 5(1):57-61. PubMed ID: 7050636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.